| Molecular and Cellular Characterization of MALT Lymphoma (NCT07376330) | International Extranodal Lymphoma Study Group (IELSG) | 2026-09-01 |
| Characterization of Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL) by Multiomic Approach (NCT07147751) | International Extranodal Lymphoma Study Group (IELSG) | 2026-09-01 |
| Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma (NCT06712459) | International Extranodal Lymphoma Study Group (IELSG) | 2025-10-13 |
| Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients (NCT05735834) | International Extranodal Lymphoma Study Group (IELSG) | 2024-05-21 |
| Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma (NCT05700149) | International Extranodal Lymphoma Study Group (IELSG) | 2024-04-11 |
| Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma (NCT04417166) | International Extranodal Lymphoma Study Group (IELSG) | 2022-02-11 |
| Study of Acalabrutinib and Tafasitamab in MZL Patients (NCT04646395) | International Extranodal Lymphoma Study Group (IELSG) | 2021-10-20 |
| FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role (NCT04333524) | International Extranodal Lymphoma Study Group (IELSG) | 2020-12-01 |
| MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas (NCT03697512) | International Extranodal Lymphoma Study Group (IELSG) | 2019-09-27 |
| Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System (NCT03495960) | International Extranodal Lymphoma Study Group (IELSG) | 2019-06-15 |